Home > Cardiology > Pendulum swings further away from aspirin for CVD primary prevention

Pendulum swings further away from aspirin for CVD primary prevention

Journal
JAMA
Reuters Health - 26/04/2022 - The U.S. Preventive Services Task Force (USPSTF) has changed its recommendation on low-dose aspirin for primary prevention of cardiovascular disease (CVD). Based on the latest available evidence, the task force now recommends against starting low-dose aspirin use for the primary prevention of CVD in adults 60 years or older (grade D; "discourage" use). The task force has also downgraded its recommendation on aspirin for primary prevention in adults aged 40 to 59 years with an estimated 10% or greater 10-year risk of CVD. The 2016 grade B recommendation (offer or provide this service) is now a grade C recommendation (offer or provide this service for selected patients depending on individual circumstances). In this group, "evidence indicates that the net benefit of aspirin use in this group is small," the task force says, and the decision to start low-dose aspirin for primary CVD prevention in this group "should be an individual o...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on